Safety and tolerability of Miltuximab ® - a first in human study in patients with advanced solid cancers

• Published in: Asia Oceania journal of nuclear medicine & biology Vol. 9; no. 2; pp. 86 - 100
• Main Authors: Sabanathan, Dhanusha, Campbell, Douglas H, Velonas, Vicki M, Wissmueller, Sandra, Mazure, Hubert, Trifunovic, Marko, Poursoltan, Pirooz, Ho Shon, Kevin, Mackay, Tiffany R, Lund, Maria E, Lu, Yanling, Roach, Paul J, Bailey, Dale L, Walsh, Bradley J, Gillatt, David, Gurney, Howard
• Format: Journal Article
• Language: English
• Published: Iran Mashhad University of Medical Sciences 2021
• Subjects: glypican-1; miltuximab; monoclonal antibody; Original; solid tumours; theranostic; Miltuximab; Monoclonal antibody Theranostic; Glypican-1; Solid tumours

Miltuximab is a chimeric antibody targeting Glypican-1 (GPC-1), a cell surface antigen which is overexpressed in solid cancers. Miltuximab has shown promising safety and efficacy in radioimmunotherapy models of prostate cancer. This first in human study used Miltuximab radiolabelled with Gallium-67...